Pim-1 expression and monoclonal antibody targeting in human leukemia cell lines

Experimental Hematology

Volumn 37, Issue 11, 2009, Pages 1284-1294

  Li, Jie ^a,b   Hu, Xiu Feng ^a   Loveland, Bruce E ^a   Xing, Pei Xiang ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; LIPOCORTIN 5; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY P9; PROPIDIUM IODIDE; PROTEIN BAD; PROTEIN KINASE PIM 1; RHODAMINE 123; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN K 562; CELL STRAIN U937; CONTROLLED STUDY; CYTOTOXICITY; DAUDI CELL; DNA SYNTHESIS; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RAJI CELL; SCID MOUSE; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA; LEUKEMIA, EXPERIMENTAL; MICE; MICE, SCID; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-PIM-1; TUMOR STEM CELL ASSAY; VERAPAMIL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 70349807583     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2009.08.002     Document Type: Article

References (53)

1. Wang Z., Bhattacharya N., Weaver M., et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2 (2001) 167-179
2. Mochizuki T., Kitanaka C., Noguchi K., Muramatsu T., Asai A., and Kuchino Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 274 (1999) 18659-18666
3. Wang Z., Bhattacharya N., Mixter P.F., Wei W., Sedivy J., and Magnuson N.S. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 1593 (2002) 45-55
4. Bachmann M., Hennemann H., Xing P.X., Hoffmann I., and Moroy T. The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 279 (2004) 48319-48328
5. Aho T.L., Sandholm J., Peltola K.J., Mankonen H.P., Lilly M., and Koskinen P.J. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 571 (2004) 43-49
6. Macdonald A., Campbell D.G., Toth R., McLauchlan H., Hastie C.J., and Arthur J.S. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol 7 (2006) 1
7. Domen J., van der Lugt N.M., Laird P.W., et al. Impaired interleukin-3 response in Pim-1-deficient bone marrow-derived mast cells. Blood 82 (1993) 1445-1452
8. Amson R., Sigaux F., Przedborski S., Flandrin G., Givol D., and Telerman A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci U S A 86 (1989) 8857-8861
9. van Lohuizen M., Verbeek S., Krimpenfort P., et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 56 (1989) 673-682
10. Breuer M., Slebos R., Verbeek S., van Lohuizen M., Wientjens E., and Berns A. Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic mice. Nature 340 (1989) 61-63
11. van der Houven van Oordt C.W., Schouten T.G., van Krieken J.H., van Dierendonck J.H., van der Eb A.J., and Breuer M.L. X-ray-induced lymphomagenesis in E mu-pim-1 transgenic mice: an investigation of the co-operating molecular events. Carcinogenesis 19 (1998) 847-853
12. Roh M., Gary B., Song C., Said-Al-Naief N., et al. Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Res 63 (2003) 8079-8084
13. Acton D., Domen J., Jacobs H., Vlaar M., Korsmeyer S., and Berns A. Collaboration of pim-1 and bcl-2 in lymphomagenesis. Curr Top Microbiol Immunol 182 (1992) 293-298
14. Schmidt T., Karsunky H., Gau E., Zevnik B., Elsasser H.P., and Moroy T. Zinc finger protein GFI-1 has low oncogenic potential but cooperates strongly with pim and myc genes in T-cell lymphomagenesis. Oncogene 17 (1998) 2661-2667
15. Schinkel A.H., and Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55 (2003) 3-29
16. Sikic B.I., Fisher G.A., Lum B.L., Halsey J., Beketic-Oreskovic L., and Chen G. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 40 Suppl (1997) S13-S19
17. Tsimberidou A.M., Paterakis G., Androutsos G., et al. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leuk Res 26 (2002) 143-154
18. Germann U.A., Pastan I., and Gottesman M.M. P-glycoproteins: mediators of multidrug resistance. Semin Cell Biol 4 (1993) 63-76
19. Damiani D., Michieli M., Michelutti A., et al. Antibody binding capacity for evaluation of MDR-related proteins in acute promyelocytic leukemia: onset versus relapse expression. Cytometry B Clin Cytom 59 (2004) 40-45
20. Pallis M., Turzanski J., Higashi Y., and Russell N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 43 (2002) 1221-1228
21. Del Poeta G., Venditti A., Stasi R., et al. P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. Leuk Res 23 (1999) 451-465
22. Tothova E., Elbertova A., Fricova M., et al. P-glycoprotein expression in adult acute myeloid leukemia: correlation with induction treatment outcome. Neoplasma 48 (2001) 393-397
23. Pallis M., and Russell N. Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia. Leukemia 18 (2004) 1927-1930
24. Aouali N., Eddabra L., Macadre J., and Morjani H. Immunosuppressors and reversion of multidrug-resistance. Crit Rev Oncol Hematol 56 (2005) 61-70
25. Arceci R.J. Mechanisms of resistance to therapy and tumor cell survival. Curr Opin Hematol 2 (1995) 268-274
26. Brenner C., Le Bras M., and Kroemer G. Insights into the mitochondrial signaling pathway: what lessons for chemotherapy?. J Clin Immunol 23 (2003) 73-80
27. Kolb J.P., Kern C., Quiney C., Roman V., and Billard C. Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Haematol Disord 3 (2003) 261-286
28. Segal-Bendirdjian E., and Jacquemin-Sablon A. [Cisplatin resistance in a murine leukemia cell line associated with defect of apoptosis]. Bull Cancer 83 (1996) 371-378
29. Krumenacker J.S., Buckley D.J., Leff M.A., et al. Prolactin-regulated apoptosis of Nb2 lymphoma cells: pim-1, bcl-2, and bax expression. Endocrine 9 (1998) 163-170
30. Moroy T., Grzeschiczek A., Petzold S., and Hartmann K.U. Expression of a Pim-1 transgene accelerates lymphoproliferation and inhibits apoptosis in lpr/lpr mice. Proc Natl Acad Sci U S A 90 (1993) 10734-10738
31. Buckley A.R., Krumenacker J.S., Buckley D.J., et al. Butyrate-induced reversal of dexamethasone resistance in autonomous rat Nb2 lymphoma cells. Apoptosis 2 (1997) 518-528
32. Xie Y., Xu K., Dai B., et al. The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene 25 (2006) 70-78
33. Hu X.F., Li J., Vandervalk S., Wang Z., Magnuson N.S., and Xing P.X. PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest 119 (2009) 362-375
34. Zalcberg J.R., Hu X.F., Wall D.M., et al. Cellular and karyotypic characterization of two doxorubicin resistant cell lines isolated from the same parental human leukemia cell line. Int J Cancer 57 (1994) 522-528
35. Xing P.X., Tjandra J.J., Stacker S.A., et al. Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol Cell Biol 67 Pt 3 (1989) 183-195
36. Hu X.F., Slater A., Rischin D., Kantharidis P., Parkin J.D., and Zalcberg J. Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line. Br J Cancer 79 (1999) 831-837
37. Broxterman H.J., Sonneveld P., Feller N., et al. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood 87 (1996) 4809-4816
38. Hu X.F., Slater A., Kantharidis P., et al. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia. Blood 93 (1999) 4086-4095
39. Xing P.X., Hu X.F., Pietersz G.A., Hosick H.L., and McKenzie I.F. Cripto: a novel target for antibody-based cancer immunotherapy. Cancer Res 64 (2004) 4018-4023
40. Fernandez-Calotti P., Jordheim L.P., Giordano M., Dumontet C., and Galmarini C.M. Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC). Leuk Lymphoma 46 (2005) 335-346
41. Meeker T.C., Nagarajan L., ar-Rushdi A., and Croce C.M. Cloning and characterization of the human PIM-1 gene: a putative oncogene related to the protein kinases. J Cell Biochem 35 (1987) 105-112
42. Nagarajan L., Louie E., Tsujimoto Y., ar-Rushdi A., Huebner K., and Croce C.M. Localization of the human pim oncogene (PIM) to a region of chromosome 6 involved in translocations in acute leukemias. Proc Natl Acad Sci U S A 83 (1986) 2556-2560
43. Pircher T.J., Zhao S., Geiger J.N., Joneja B., and Wojchowski D.M. Pim-1 kinase protects hematopoietic FDC cells from genotoxin-induced death. Oncogene 19 (2000) 3684-3692
44. Mizuno K., Shirogane T., Shinohara A., Iwamatsu A., Hibi M., and Hirano T. Regulation of Pim-1 by Hsp90. Biochem Biophys Res Commun 281 (2001) 663-669
45. Losman J.A., Chen X.P., Vuong B.Q., Fay S., and Rothman P.B. Protein phosphatase 2A regulates the stability of Pim protein kinases. J Biol Chem 278 (2003) 4800-4805
46. Shay K.P., Wang Z., Xing P.X., McKenzie I.F., and Magnuson N.S. Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol Cancer Res 3 (2005) 170-181
47. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., and Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5 (2006) 219-234
48. Laird P.W., van der Lugt N.M., Clarke A., et al. In vivo analysis of Pim-1 deficiency. Nucleic Acids Res 21 (1993) 4750-4755
49. Martin-Aragon S., Mukherjee S.K., Taylor B.J., et al. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs. Anticancer Res 20 (2000) 139-150
50. Xie Y., Xu K., Linn D.E., et al. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem 283 (2008) 3349-3356
51. Mao Q., and Unadkat J.D. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7 (2005) E118-E133
52. Garcia-Escarp M., Martinez-Munoz V., Sales-Pardo I., et al. Flow cytometry-based approach to ABCG2 function suggests that the transporter differentially handles the influx and efflux of drugs. Cytometry A 62 (2004) 129-138
53. Zhang Y., Gupta A., Wang H., et al. BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res 22 (2005) 2023-2034